154 related articles for article (PubMed ID: 36549170)
1. Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis.
Petrelli F; Bertaglia V; Parati MC; Borgonovo K; De Silva P; Luciani A; Novello S; Scartozzi M; Emens LA; Solinas C
Breast; 2023 Feb; 67():8-13. PubMed ID: 36549170
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
Li Y; Zhou Y; Mao F; Lin Y; Zhang X; Shen S; Sun Q
Breast Cancer Res Treat; 2020 Feb; 179(3):533-542. PubMed ID: 31865475
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study.
Roy S; Lakritz S; Schreiber AR; Molina E; Kabos P; Wood M; Elias A; Kondapalli L; Bradley CJ; Diamond JR
Eur J Cancer; 2023 May; 185():69-82. PubMed ID: 36965330
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101.
Narui K; Ishikawa T; Shimizu D; Yamada A; Tanabe M; Sasaki T; Oba MS; Morita S; Nawata S; Kida K; Mogaki M; Doi T; Tsugawa K; Ogata H; Ota T; Kosaka Y; Sengoku N; Kuranami M; Niikura N; Saito Y; Suzuki Y; Suto A; Arioka H; Chishima T; Ichikawa Y; Endo I; Tokuda Y
Breast; 2019 Oct; 47():1-9. PubMed ID: 31229857
[TBL] [Abstract][Full Text] [Related]
5. First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis.
Jiang Y; Yin W; Zhou L; Yan T; Zhou Q; Du Y; Shen Z; Shao Z; Lu J
PLoS One; 2012; 7(3):e32474. PubMed ID: 22396769
[TBL] [Abstract][Full Text] [Related]
6. Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis.
Zhao F; Shen G; Dong Q; Xin Y; Huo X; Wang M; Liu Z; Zhao Y; Ren D; Xie Q; Liu Z; Li Z; Gao L; Du F; Zhao J
Clin Exp Med; 2023 Oct; 23(6):2025-2040. PubMed ID: 36422737
[TBL] [Abstract][Full Text] [Related]
7. Different Chemotherapy Regimens and Pathologic Complete Response in Triple-Negative Breast Cancer: An Updated Network Meta-Analysis of Phase 3 Trials.
Petrelli F; Tomasello G; Parati MC; Ghidini A; Ghidini M; Borgonovo K; Cabiddu M; Ghilardi M; Reduzzi R; Gambini D; Zaniboni A; Faustinelli G; Garrone O
Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399628
[No Abstract] [Full Text] [Related]
8. Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study.
Roy S; Lakritz S; Schreiber AR; Kuna EM; Bradley CJ; Kondapalli L; Diamond JR
Eur J Cancer; 2024 Jan; 196():113426. PubMed ID: 38000217
[TBL] [Abstract][Full Text] [Related]
9. The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Huo X; Li J; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
BMC Cancer; 2021 Jan; 21(1):78. PubMed ID: 33468087
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis.
Lin YY; Gao HF; Yang X; Zhu T; Zheng XX; Ji F; Zhang LL; Yang CQ; Yang M; Li JQ; Cheng MY; Wang K
Breast; 2022 Dec; 66():126-135. PubMed ID: 36265208
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane.
Lee A; Go SI; Lee WS; Lee US; Kim MJ; Kang MH; Lee GW; Kim HG; Kang JH; Jeon KN; Cho JM; Lee JH
Tumori; 2015 Mar; 101(1):e9-e12. PubMed ID: 25702650
[TBL] [Abstract][Full Text] [Related]
12. Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
Ren YX; Hao S; Jin X; Ye FG; Gong Y; Jiang YZ; Shao ZM
Breast; 2019 Feb; 43():97-104. PubMed ID: 30529406
[TBL] [Abstract][Full Text] [Related]
13. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
Absmaier M; Napieralski R; Schuster T; Aubele M; Walch A; Magdolen V; Dorn J; Gross E; Harbeck N; Noske A; Kiechle M; Schmitt M
Int J Oncol; 2018 Mar; 52(3):755-767. PubMed ID: 29328369
[TBL] [Abstract][Full Text] [Related]
14. Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
Caparica R; Bruzzone M; Poggio F; Ceppi M; de Azambuja E; Lambertini M
Breast Cancer Res Treat; 2019 Feb; 174(1):27-37. PubMed ID: 30465156
[TBL] [Abstract][Full Text] [Related]
15. Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis.
Pathak N; Sharma A; Elavarasi A; Sankar J; Deo SVS; Sharma DN; Mathur S; Kumar S; Prasad CP; Kumar A; Batra A
Breast; 2022 Aug; 64():7-18. PubMed ID: 35462344
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer.
Xi X; Huang X; Yuan H; Ni J; Yang F
J Healthc Eng; 2022; 2022():7430775. PubMed ID: 35265304
[TBL] [Abstract][Full Text] [Related]
17. Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials.
Ye F; Bian L; Wen J; Yu P; Li N; Xie X; Wang X
BMC Cancer; 2022 Mar; 22(1):261. PubMed ID: 35279130
[TBL] [Abstract][Full Text] [Related]
18. Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer.
Chen W; Tu Q; Shen Y; Tang K; Hong M; Shen Y
World J Surg Oncol; 2021 Feb; 19(1):52. PubMed ID: 33602236
[TBL] [Abstract][Full Text] [Related]
19. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).
Lluch A; Barrios CH; Torrecillas L; Ruiz-Borrego M; Bines J; Segalla J; Guerrero-Zotano Á; García-Sáenz JA; Torres R; de la Haba J; García-Martínez E; Gómez HL; Llombart A; Bofill JS; Baena-Cañada JM; Barnadas A; Calvo L; Pérez-Michel L; Ramos M; Fernández I; Rodríguez-Lescure Á; Cárdenas J; Vinholes J; Martínez de Dueñas E; Godes MJ; Seguí MA; Antón A; López-Álvarez P; Moncayo J; Amorim G; Villar E; Reyes S; Sampaio C; Cardemil B; Escudero MJ; Bezares S; Carrasco E; Martín M; ; ;
J Clin Oncol; 2020 Jan; 38(3):203-213. PubMed ID: 31804894
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy.
Li M; Ma F; Wang J; Li Q; Zhang P; Yuan P; Luo Y; Cai R; Fan Y; Chen S; Li Q; Xu B
Chin J Cancer; 2018 Jan; 37(1):4. PubMed ID: 29382381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
